Skip to main content
Erschienen in: Thrombosis Journal 1/2019

Open Access 01.12.2019 | Research

Effects of glycemic control and hypoglycemia on Thrombus formation assessed using automated microchip flow chamber system: an exploratory observational study

verfasst von: Kiyoaki Yamamoto, Takashi Ito, Tomoka Nagasato, Atsushi Shinnakasu, Mihoko Kurano, Aiko Arimura, Hiroshi Arimura, Hiroshi Hashiguchi, Takahisa Deguchi, Ikuro Maruyama, Yoshihiko Nishio

Erschienen in: Thrombosis Journal | Ausgabe 1/2019

Abstract

Background

Thrombus formation is an important factor affecting cardiovascular events and venous thromboembolism in type 2 diabetes. However, it is unclear whether glycemic control reduces thrombogenicity. We investigated the effect of short-term glycemic control (STUDY 1) and hypoglycemia (STUDY 2) on thrombus formation using an automated microchip flow chamber system.

Methods

For STUDY 1, we recruited 10 patients with type 2 diabetes. Before and after 2 weeks of treatment, blood glucose was analyzed with a continuous glucose monitoring system, and thrombogenicity was analyzed with an automated microchip flow chamber system. For STUDY 2, we recruited 10 subjects without diabetes who underwent an insulin tolerance test. We evaluated the change in thrombogenic potential with hypoglycemia.

Results

STUDY1: The mean blood glucose level reduced from 10.1 ± 2.6 to 6.9 ± 0.97 mM (P < 0.01). T10, an indicator of thrombogenicity, significantly attenuated after glycemic control (338 ± 65 vs. 425 ± 117 s, P < 0.05). The attenuation in T10 was significantly correlated with changes in mean blood glucose level after treatment (r = − 0.718, P < 0.05). STUDY 2: Platelet function was enhanced with decreasing blood glucose; increased platelet function was strongly correlated with an increase in epinephrine.

Conclusions

We demonstrated attenuation in thrombogenicity with short-term comprehensive diabetes care and enhancement in thrombogenicity with hypoglycemia, using a new flow chamber system.

Trial registration

UMIN-CTR UMIN 000019899, registered 26-Jan-2015 (STUDY 2).
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12959-019-0206-8) contains supplementary material, which is available to authorized users.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AR-AUC30
area under the flow curve in 30 min
AR-OT
occlusion time: time to 80 kPa
AR-T10
time to 10 kPa
CGM
Continuous glucose monitoring
DOAC
Direct-acting oral coagulants
F1 + 2
Prothrombin fragment 1 + 2
FPG
Fasting plasma glucose
FVII
Factor VII
FVIII
Factor VIII
Ht
Hematocrit
MAGE
Mean amplitude of glycemic excursion
PAI-1
Plasminogen activator 1
PL-AUC10
area under the flow curve in 10 min
PL-OT
occlusion time: time to 60 kPa
PL-T10
time to 10 kPa
PRP
Platelet-rich plasma
SD
Standard deviation
T-TAS
Total Thrombus formation Analysis System
WBC
White blood cell

Background

Atherothrombotic disease is a major cause of death in patients with diabetes [1]. The mechanism of increased thrombosis in patients with diabetes involves multiple pathways. Thrombus formation, the last step in the atherothrombotic process, is an important factor influencing the risk and prognosis associated with cardiovascular events [2]. Moreover, diabetes is a risk factor for arterial and venous thrombosis. A recent meta-analysis found that patients with diabetes were at increased risk of developing venous thromboembolism (VTE), which can occur in a hypercoagulable state [3].
Several studies have shown that patients with diabetes have increased thrombogenicity owing to platelet hyperreactivity, activation of coagulation factors and hypo-fibrinolysis [46]. However, it is unclear whether glycemic control reduces thrombus formation. Especially, the influence of glycemic control over short periods of time, such as one or two weeks, has not been assessed, even though it is a clinically-important issue for preventing post-surgical complications [7].
On the other hand, evidence is accumulating that hyperglycemia and hypoglycemia, which can occur when trying to achieve strict glycemic control, is associated with increased risk of cardiovascular and cerebrovascular death. In the ACCORD study, the mortality rate was higher in the strict-treatment than in the standard-treatment group [8]. The involvement of hypoglycemia as a risk factor for thrombosis is a topic of active discussion.
A previous study evaluated thrombogenicity using plasma markers [9] and platelet function tests with an agonist, above physiological concentrations; however, the effects of blood flow were not considered and blood flow is a well-known influence on the thrombus formation process [10]. Therefore, it is necessary to evaluate thrombogenicity comprehensively, using close-to-physiological conditions and considering blood flow. Recently, a Total Thrombus formation Analysis System (T-TAS, Fujimori Kogyo Co., Yokohama, Kanagawa) [11] was found useful [12] for quantitative analysis of thrombus formation. The T-TAS continuously monitors the pressure on microchips with thrombogenic surfaces that simulate pathological blood vessels [11, 13]. Compared with conventional systems, the T-TAS can evaluate thrombogenicity under blood flow conditions; therefore, it is possible to perform analyses that more closely resemble in vivo conditions.
This pilot study aimed at investigating the influence of short-term glycemic control (STUDY 1) and change in hypoglycemia (STUDY 2) on thrombus formation using T-TAS.

Materials and methods

Study 1

Glycemic control efforts were started immediately after hospitalisation. Blood glucose levels were controlled with insulin, GLP-1 analogues and oral hypoglycemic agents. The goal of treatment was to achieve a fasting plasma glucose (FPG) level < 7.2 mM and a postprandial PG level < 11.1 mM. A continuous glucose monitoring (CGM) device (iPro2: Medtronic Minimed, Northridge, CA, USA) was attached to each patient from the day of hospitalization, and monitoring was performed for 3 days. Blood collection and evaluation for T-TAS were carried out on the day after hospitalization. These evaluations were performed again after glycemic control was achieved. The exclusion criteria were antiplatelet drug or anticoagulant use, infectious diseases, malignant tumors, drug-induced diabetes, ketoacidosis and possible pregnancy.

Blood samples

Following overnight fasting, blood was drawn for the measurement of blood glucose, hematocrit (Ht), platelet, plasminogen activator inhibitor 1 (PAI-1), fibrinogen, factor VII (FVII), factor VIII (FVIII) and prothrombin fragment 1 + 2 (F1 + 2), and for assessment using T-TAS.
Glucose levels were measured using a GA echo buffer solution, Glucose BP standard solution and automated glucose analyzer GA08III (A&T corporation, Kanagawa, Japan). The LPIA·tPAI test with the automated immunoanalyzer STACIA (LSI Medience Corporation, Tokyo, Japan) for PAI-1, Thrombo check Fib (L) with CS-5100 Automated Coagulation Analyzer (Sysmex Corporation, Hyogo, Japan) for fibrinogen, HemosIL RecombiPlasTin or HemosIL Synth Asil with ACL TOP automated analyzer (Instrumentation Laboratory, Bedford, MA) for FVII or FVII and Enzygnost with Microplate Reader Emax (Molecular Devices Japan, Tokyo, Japan) for F1 + 2 were applied respectively.

CGM

We used a CGM device and considered the result as an indicator of short-term glycemic control. The mean blood glucose level, peak blood glucose levels and standard deviation (SD) and mean amplitude of glycemic excursion (MAGE) were calculated from the results.

T-TAS

T-TAS evaluations were carried out using two kinds of microchips (PL chip and AR chip). The PL chip, which is coated with collagen, represents platelet thrombus formation. The AR chip, which is coated with collagen plus tissue thromboplastin, represents thrombus formation mediated by the coagulo-fibrinolysis system and platelets. Whole blood anticoagulated with hirudin was perfused through the PL chip at a shear rate of 1500 S− 1; then, PL-T10 (time to 10 kPa), PL-OT (occlusion time: time to 60 kPa) and PL-AUC10 (area under the flow curve in 10 min) were used to evaluate thrombus formation. Recalcified whole blood containing corn trypsin inhibitor was perfused through the AR chip at a sheer rate of 600 S− 1; then, AR-T10 (time to 10 kPa), AR-OT (occlusion time: time to 80 kPa) and AR-AUC30 (area under the flow curve in 30 min) were evaluated. The intra-assay coefficient of variability of PL-AUC and AR-AUC are 5.85 and 1.24% respectively (Additional file 1: Figure S1). The reference ranges (mean ± SD) of PL-T10, PL-OT and PL-AUC in healthy volunteers were reported to be 163 ± 51 s, 347 ± 96 s, and 369.1 ± 71.8 kPa × min, respectively [14].

Study 2

Human regular insulin (Eli Lilly, Indianapolis, IN) was injected intravenously at a dose of 0.05–0.10 U/kg body weight. Blood samples for glucose and epinephrine were collected before the injection and at 15, 30, 45, 60, 90 and 120 min after the injection; for T-TAS blood samples were collected before the injection and at 15, 30, 60, 90 and 120 min; and for WBC blood samples were collected before the injection and at 30 and 60 min after the injection. For measurement of epinephrine, the CA Test 「TOSOH」 (Tosoh Corporation, Tokyo, Japan) and HPLC system (SHIMADZU CORPORATION, Kyoto, Japan) were used.

Statistical analysis

Normally distributed data are presented as means ± SDs, and the paired t-test was used to assess the presence of significant differences. Non-normally distributed data are presented as medians (quartile range), and the Wilcoxon signed rank test was used for assessment. Spearman’s rank correlation was used for assessing correlation. IBM SPSS 20 statistical package (IBM Corp., Armonk, NY) was used to perform all the statistical analyses. A P-value < 0.05 was considered statistically significant.

Results

Study 1

We included 10 patients with type 2 diabetes who were admitted to Kagoshima University Hospital for glycemic control (Table 1) (Additional file 1: Table S1). The mean duration of the period between pre- and post-glycemic control was 10.4 days. The levels of fasting plasma glucose (FPG) reduced from 9.6 ± 2.3 mM to 6.3 ± 1.4 mM (P < 0.01), mean blood glucose reduced from 10.1 ± 2.5 mM to 6.8 ± 0.9 mM (P < 0.01), and peak blood glucose reduced from 15.6 ± 4.3 mM to 11.5 ± 4.1 mM (P < 0.05). The SD of blood glucose and MAGE were unchanged (2.1 ± 1.3 mM vs. 1.6 ± 1.2 mM, P = 0.24 and 87.5 ± 42.4 vs. 68.5 ± 51.2, P = 0.31, respectively) (Table 2). In one case, mild hypoglycemia (3.1 mM) was recognized in the night during CGM; however, this was not observed in other patients.
Table 1
Patient characteristics in STUDY 1
Age (years)
47.5 ± 16.6
Sex (male/female)
5 / 5
BMI (kg/m2)
29.6 ± 7.9
FPG (mM)
10.2 ± 3.0
HbA1c (%)
10.5 ± 3.1
Duration of diabetes (years)
4.8 ± 4.0
Systolic blood pressure (mmHg)
121.1 ± 13.3
Diastolic blood pressure (mmHg)
77.7 ± 12.0
LDL cholesterol (mM)
2.9 ± 1.3
HDL cholesterol (mM)
1.3 ± 0.4
Triglyceride (mM)
1.8 ± 1.1
eGFR (mL/min/1.73 m2)
99.4 ± 21.1
Values are presented as mean ± standard deviation (SD)
FPG fasting plasma glucose
Table 2
Parameters of haematologic data, CGMs and T-TAS before and after glycemic control in STUDY 1
 
Baseline
After control
P-value
FPG (mM)
9.6 ± 2.3
6.3 ± 1.4
0.004
Hematologic parameters
 WBC count (/μL)
5752 ± 1440
5468 ± 1342
0.191
 Ht (%)
41.1 ± 4.8
40.7 ± 4.9
0.523
 Plt count (104 /μL)
19.3 (16.6–24.2)
20.2 (18.9–24.1)
0.683
 PAI-1 (ng/mL)
24.0 (16.3–45.3)
21.0 (14.5–28.5)
0.211
 Fibrinogen (g/dL)
3.3 ± 0.7
3.6 ± 0.3
0.128
 Factor VII (%)
85.4 ± 8.6
83.6 ± 11.2
0.522
 Factor VIII (%)
101.1 ± 33.4
92.3 ± 28.7
0.288
 F1 + 2 (pM)
135.5 (105.0–169.3)
139.5 (107.3–173.5)
0.580
CGMs
 Mean PG (mM)
10.1 ± 2.5
6.8 ± 0.9
0.005
 Peak PG (mM)
16.3 (11.3–19.1)
10.2 (8.8–12.4)
0.017
 SD (mM)
1.8 (1.2–2.4)
1.1 (0.9–1.7)
0.242
 MAGE (mM)
4.3 (2.9–7.0)
2.8 (2.2–4.1)
0.310
T-TAS
 PL-T10 (s)
125.5 (110.8–141.0)
126.0 (120.5–135.3)
0.881
 PL-OT (s)
327.8 ± 67.6
308.7 ± 56.5
0.166
 PL-AUC10 (kPa × min)
393.2 ± 45.3
398.3 ± 32.2
0.647
Values are presented as mean ± standard deviation (SD) or median (quartile range)
WBC white blood cell, Ht hematocrit, Plt platelet, PAI-1 plasminogen activator inhibitor-1, F1 + 2 prothrombin fragment 1 + 2, FPG fasting plasma glucose, MAGE mean amplitude of glycemic excursions, T10 time to 10 kPa, OT occlusion time, AUC10 area under the curve in 10 min
Hematologically, no significant changes were observed in WBC count, Ht level, platelet count, fibrinolysis marker (PAI-1) level and coagulation marker (fibrinogen, FVII, FVIII, F1 + 2) levels (Table 2).
In STUDY 1, the T-TAS and two microchips were used to evaluate thrombus formation. Inside the PL chip, activation of the platelet is triggered on the surface of collagen [13]. Inside the other AR chip, activation of both platelets and coagulation is triggered by collagen and tissue thromboplastin [11]. We evaluated thrombogenicity by assessing the changes in flow pressure during thrombus formation.
AR-T10 and AR-OT increased from 337.8 ± 64.7 s to 425.2 ± 116.9 s (P = 0.005) and from 441.2 ± 73.0 s to 527.7 ± 115.4 s (P = 0.006), respectively, while AR-AUC30 reduced from 1890.3 ± 91.3 to 1775.9 ± 154.5 kPa × min (P = 0.006) (Fig. 1). No PL chip parameters changed (Table 2).
We compared the change in the mean PG (Δmean PG) and SD (ΔSD) with the change in T-TAS parameters (Fig. 2). The change in AR-T10 (ΔAR-T10) was significantly correlated with Δmean PG after treatment (r = − 0.718, P < 0.05), but not with FPG, SD and MAGE.
Although the correlation between Δmean PG and ΔAR-OT or ΔAR-AUC30 was not statistically significant, non-significant trend was observed. Additional file 1: Table S2 presents individual data on mean PG, AR-T10, AR-OT and AR-AUC30 in STUDY 1.

Study 2

We included 10 patients who underwent an insulin tolerance test for hypothalamic pituitary evaluation (Table 3). After insulin injection, PG decreased from 5.2 ± 0.7 mM (baseline) to 1.7 ± 0.5 mM (45 min), and Ht increased from 37.5 ± 3.5% to 39.1 ± 3.7% (P < 0.01) and epinephrine increased from 19.5 ± 11.2 pg/mL to 449.5 ± 289.6 pg/mL (P < 0.01). However, the platelet count did not change (24.5 × 104/μL to 25.8 × 104/μL, P = 0.053).
Table 3
Patient characteristics in STUDY 2
Age (years)
46.8 ± 14.8
Sex (male/female)
3 / 7
BMI (kg/m2)
24.1 ± 3.3
HbA1c (%)
5.7 ± 0.5
Systolic blood pressure (mmHg)
121.7 ± 14.5
Diastolic blood pressure (mmHg)
75.6 ± 11.5
eGFR (mL/min/1.73 m2)
97.3 ± 18.6
Values are presented as mean ± standard deviation (SD)
FPG fasting plasma glucose; BMI, body mass index
PL-T10 decreased from 156.4 ± 55.5 s to 109.7 ± 15.2 s (P < 0.05), while PL-AUC10 increased from 380.3 ± 72.4 s to 428.3 ± 31.9 s (P < 0.05). PL-T10 was significantly lower, and PL-AUC10 was significantly higher, at 60 min compared to the baseline values (Fig. 3c, d).
Along with hypoglycemia, epinephrine and WBC count significantly changed (Fig. 3e). In addition, there was a correlation between the decrease in PG (ΔPG) and the change in epinephrine (Δepinephrine). Furthermore, Δepinephrine was correlated with ΔPL-T10 and ΔPL-AUC10 (Fig. 4). We found the significant correlations between ΔPL-T10 and change in Ht (r = − 0.772, P = 0.009), change in WBC count (r = − 0.915, P < 0.001) or change in platelet count (r = − 0.648, P = 0.043) (Additional file 1: Figure S2). Additional file 1: Table S3 shows individual data on the PG, epinephrine, PL-T10 and PL-AUC10 in STUDY2.

Discussion

We aimed to elucidate the effects of short-term glycemic control on blood thrombogenicity in patients with diabetes (STUDY1) and change of platelet function during hypoglycemia (STUDY2) using a newly-developed, microchip-based flow chamber system. We used two types of microchips [13]: the PL chip to evaluate thrombogenicity, mainly involving platelets, and the AR chip to evaluate platelet activation and the coagulo-fibrinolytic reaction [11].
Although it has been reported that thrombogenic potential improves as glycemic control improves, for at least several months [15], it was not clear whether short-term control reduces thrombus formation. Our study (STUDY1) demonstrated that short-term glycemic control attenuates thrombogenicity. Of note, improvements in mean blood glucose level, but not glucose excursion, were strongly correlated with reduced thrombogenicity. In impaired glucose tolerance patients, it has been reported that suppression of postprandial hyperglycemia can prevent the onset of cardiovascular events [16]. But in type 2 diabetic patients, the protective effect of the attenuation of glucose spikes remains controversial [17]. Furthermore, there is a large-scale clinical research showing that the cardiovascular risk is lower in patients with low HbA1c values, which represent low mean blood glucose levels [18]. These results underscore the clinical significance of short-term pre-operative glycemic control to improve patients’ prognosis.
The mean value of AR-OT before glycemic control was 425.2 s, shorter than the mean value in healthy adults (489 +/− 96 s, unpublished data). After glycemic control, AR-OT improved to 527.7 s. The other AR chip parameters (AR-T10 and AR-AUC30) also improved after glycemic control. The PL chip parameters, which represent platelet-mediated thrombogenicity, showed no attenuation.
One possible explanation for the reduced thrombogenicity of the AR chip, without attenuation of PL chip thrombogenicity and coagulo-fibrinolysis markers, is glycation of fibrinogen and plasminogen because of high blood glucose. In the studies that used the purified-fibrinogen model, chronic hyperglycemia accelerated glycation of fibrinogen non-enzymatically. Glycated fibrinogen rapidly constructed a fibrin network, increasing the resistance to the fibrinolytic system, compared to non-diabetic patients [19, 20], due to changes in the kinetics of fibrin polymerization [20]. Past reports found that patients with diabetes and rapidly-improving glycemic control had significantly decreased glycated fibrinogen over 3 days [21]. In patients with diabetes, glycation of plasminogen reduced plasmin generation and impaired plasminogen function, both of which were ameliorated by glycemic control [22]. Based on these results, the hypo-fibrinolytic state may have improved secondary to decreases in glycated fibrinogen and plasminogen, even during short-term glycemic control.
It is not clear what factor, among all those altered by comprehensive diabetes care, contributed to the attenuation of thrombotic occlusion. Since the decrease in the mean PG change showed a relatively strong negative correlation with the change in AR-T10, mean PG might be an important factor. However, it is also possible that some specific treatment options, such as metformin, glucagon-like peptide-1 receptor agonists or statins, contribute to reduction of thrombogenic potentials. A large-scale study with a stratified analysis is necessary to examine this issue further.
The findings of this study differ from the findings of previous studies [23, 24] of the relationship between glycemic control and thrombogenicity. Several reported that levels of fibrinogen, PAI-1, FVII, FVIII and F1 + 2 are increased in patients with diabetes [25]; however, in the present study, the levels were within normal limits and did not change after glycemic control. These markers are influenced by various factors, such as low-grade inflammation [26], insulin resistance [27] and hyperglycemia itself [28]; therefore, our results may reflect differences in patients’ backgrounds.
The relationship between glycemic control and platelet function is controversial [29, 30]. Factors other than the glucose level may be involved in platelet function among patients with type 2 diabetes [31]. In a previous clinical study, aspirin administered for primary prevention in patients with type 2 diabetes failed to reduce the risk of macrovascular events [32]. The role of platelets in thrombus formation, among patients with type 2 diabetes, may be limited.
Conventionally, there is a recognized relationship between hypoglycaemia and increased platelet function [33]. However, prior results were verified in the absence of blood flow or with supra-physiological concentrations. Moreover, the samples consisted of platelet-rich plasma (PRP) and not whole blood. To the best of our knowledge, this is the first study to evaluate thrombus formation associated with hypoglycaemia using a flow chamber system with microchips simulated pathological blood vessels.
Platelet function was enhanced with decreasing blood glucose, and increased platelet function was strongly correlated with an increase in epinephrine (STUDY2). Several studies have shown that plasma epinephrine may have an important role in platelet activation during hypoglycemia in patients with type 2 diabetes [34, 35]. Epinephrine is secreted from the adrenal medulla through the activation of the sympathetic nervous system as a physiological defence when PG levels fall [36]. Increased epinephrine levels cause platelet aggregation through the activation of α2-adrenergic receptors [37]. Additionally, the changes in WBC count and Ht levels correlated with changes in PL chip parameters. Increased WBC count, partially that induced by epinephrine, may contribute to thrombus formation and progress. WBCs, especially monocytes and neutrophils, induce thrombus formation in collaboration with platelets [38]. Furthermore, increased Ht level after insulin injection could have affected blood viscosity inside the PL chip.
Our patients included one with acromegaly and one with adrenal insufficiency; however, there was no association of cortisol and growth hormone levels with platelet function [39].
It has been reported that, in patients with acute coronary syndrome, hyperglycemia is associated with poor prognosis and high rates of subsequent ischaemic events [40]. However, there is no firm evidence that glycemic control improves prognosis in patients who have experienced cardiovascular events. Our results suggest that glycemic control improves prognosis in critical situations and underscore the importance of avoiding hypoglycemia.
Although there is no study on the relationship between glycemic control and development of VTE, glycemic control-related improvements in the hypo-fibrinolysis state may lower the risk of VTE while improving prognosis.
Earlier studies investigated the effects of anti-platelet or anti-coagulant drugs on T-TAS measurements [41, 42]. One study that evaluated the effects of warfarin or direct-acting oral coagulants (DOACs) with T-TAS [43] showed a decrease in AR-AUC30, similar to the results of STUDY 1. Changes in T-TAS parameters, obtained by comprehensive diabetes care involving short-term glycemic control, appear physiologically-relevant.
Our study has several limitations. First, the number of participants was small. Nevertheless, we think that our preliminary findings are worth reporting and may inform future, more scientifically-rigorous studies. Second, we enrolled patients without diabetes in STUDY 2, because patients with diabetes have increased risk of ischaemic events associated with hypoglycaemia. Third, we did not evaluate thrombus formation with the AR chip in STUDY2. Interpretation of AR chip results might be difficult if significant changes in platelet function are observed because the AR chip results reflected either platelet aggregation or coagulation factor. Finally, we could not obtain direct evidence of glycated state alteration.

Conclusions

In summary, we demonstrated attenuation in thrombogenicity with comprehensive diabetes care and enhancement in thrombogenicity with hypoglycemia, using a new flow chamber system. To confirm these findings, further large-scale clinical studies are needed.

Acknowledgements

None.
The present study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Kagoshima University Graduate School of Medicine and Dentistry and registered under UMIN000019899 (STUDY 2). All the patients provided written informed consent to participate.
Not applicable.

Competing interests

T-TAS is a product of Fujimori Kogyo Co., Ltd. where T.N. are employed. I.M. received research support from Fujimori Kogyo Co., Ltd., however, it is for academic promotion and is not directly related to this study. The remaining authors have disclosed they do not have any conflicts of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.CrossRef Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.CrossRef
2.
Zurück zum Zitat Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.CrossRef Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.CrossRef
3.
Zurück zum Zitat Gariani K, Mavrakanas T, Combescure C, Perrier A, Marti C. Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies. Eur J Intern Med. 2016;28:52–8.CrossRef Gariani K, Mavrakanas T, Combescure C, Perrier A, Marti C. Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies. Eur J Intern Med. 2016;28:52–8.CrossRef
4.
Zurück zum Zitat Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–8.CrossRef Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–8.CrossRef
5.
Zurück zum Zitat Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007;92:4352–8.CrossRef Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007;92:4352–8.CrossRef
6.
Zurück zum Zitat Seljeflot I, Larsen JR, Dahl-Jorgensen K, Hanssen KF, Arnesen H. Fibrinolytic activity is highly influenced by long-term glycemic control in type 1 diabetic patients. J Thromb Haemost. 2006;4:686–8.CrossRef Seljeflot I, Larsen JR, Dahl-Jorgensen K, Hanssen KF, Arnesen H. Fibrinolytic activity is highly influenced by long-term glycemic control in type 1 diabetic patients. J Thromb Haemost. 2006;4:686–8.CrossRef
7.
Zurück zum Zitat Newman JD, Wilcox T, Smilowitz NR, Berger JS. Influence of diabetes on trends in perioperative cardiovascular events. Diabetes Care. 2018. Newman JD, Wilcox T, Smilowitz NR, Berger JS. Influence of diabetes on trends in perioperative cardiovascular events. Diabetes Care. 2018.
8.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRef Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRef
9.
Zurück zum Zitat Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complicat. 1998;12:181–6.CrossRef Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complicat. 1998;12:181–6.CrossRef
10.
Zurück zum Zitat Brass LF, Diamond SL. Transport physics and biorheology in the setting of hemostasis and thrombosis. J Thromb Haemost. 2016;14:906–17.CrossRef Brass LF, Diamond SL. Transport physics and biorheology in the setting of hemostasis and thrombosis. J Thromb Haemost. 2016;14:906–17.CrossRef
11.
Zurück zum Zitat Hosokawa K, Ohnishi T, Kondo T, Fukasawa M, Koide T, Maruyama I, Tanaka KA. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost. 2011;9:2029–37.CrossRef Hosokawa K, Ohnishi T, Kondo T, Fukasawa M, Koide T, Maruyama I, Tanaka KA. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost. 2011;9:2029–37.CrossRef
12.
Zurück zum Zitat Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost. 2013;109:102–11.CrossRef Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost. 2013;109:102–11.CrossRef
13.
Zurück zum Zitat Hosokawa K, Ohnishi T, Fukasawa M, Kondo T, Sameshima H, Koide T, Tanaka KA, Maruyama I. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res. 2012;83:154–61.CrossRef Hosokawa K, Ohnishi T, Fukasawa M, Kondo T, Sameshima H, Koide T, Tanaka KA, Maruyama I. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res. 2012;83:154–61.CrossRef
14.
Zurück zum Zitat Yamaguchi Y, Moriki T, Igari A, Matsubara Y, Ohnishi T, Hosokawa K, Murata M. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res. 2013;132:263–70.CrossRef Yamaguchi Y, Moriki T, Igari A, Matsubara Y, Ohnishi T, Hosokawa K, Murata M. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res. 2013;132:263–70.CrossRef
15.
Zurück zum Zitat Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38:1307–12.CrossRef Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38:1307–12.CrossRef
16.
Zurück zum Zitat Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.CrossRef Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.CrossRef
17.
Zurück zum Zitat Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:381–6.CrossRef Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:381–6.CrossRef
18.
Zurück zum Zitat Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321:405–12.CrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321:405–12.CrossRef
19.
Zurück zum Zitat Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198–206.CrossRef Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198–206.CrossRef
20.
Zurück zum Zitat Pieters M, Covic N, van der Westhuizen FH, Nagaswami C, Baras Y, Toit Loots D, Jerling JC, Elgar D, Edmondson KS, van Zyl DG, et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost. 2008;99:691–700.CrossRef Pieters M, Covic N, van der Westhuizen FH, Nagaswami C, Baras Y, Toit Loots D, Jerling JC, Elgar D, Edmondson KS, van Zyl DG, et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost. 2008;99:691–700.CrossRef
21.
Zurück zum Zitat Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RD: Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 1989, 26 ( Pt 1):58–62.CrossRef Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RD: Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 1989, 26 ( Pt 1):58–62.CrossRef
22.
Zurück zum Zitat Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, Dunn EJ, Anwar MM, Rabbani N, Thornalley PJ, et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013;122:134–42.CrossRef Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, Dunn EJ, Anwar MM, Rabbani N, Thornalley PJ, et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013;122:134–42.CrossRef
23.
Zurück zum Zitat Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res. 2006;34:545–55.CrossRef Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res. 2006;34:545–55.CrossRef
24.
Zurück zum Zitat Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;125:653–7.CrossRef Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;125:653–7.CrossRef
25.
Zurück zum Zitat Barazzoni R, Kiwanuka E, Zanetti M, Cristini M, Vettore M, Tessari P. Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes. 2003;52:1851–6.CrossRef Barazzoni R, Kiwanuka E, Zanetti M, Cristini M, Vettore M, Tessari P. Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes. 2003;52:1851–6.CrossRef
26.
Zurück zum Zitat Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, Perez A, Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009;32:932–7.CrossRef Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, Perez A, Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009;32:932–7.CrossRef
27.
Zurück zum Zitat Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT angina pectoris study group. Arterioscler Thromb. 1993;13:1865–73.CrossRef Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT angina pectoris study group. Arterioscler Thromb. 1993;13:1865–73.CrossRef
28.
Zurück zum Zitat Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988;31:889–91.CrossRef Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988;31:889–91.CrossRef
29.
Zurück zum Zitat Konya H, Hasegawa Y, Hamaguchi T, Satani K, Umehara A, Katsuno T, Ishikawa T, Miuchi M, Kohri K, Suehiro A, et al. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism. 2010;59:1294–9.CrossRef Konya H, Hasegawa Y, Hamaguchi T, Satani K, Umehara A, Katsuno T, Ishikawa T, Miuchi M, Kohri K, Suehiro A, et al. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism. 2010;59:1294–9.CrossRef
30.
Zurück zum Zitat Singer J, Weissler Snir A, Leshem-Lev D, Rigler M, Kornowski R, Lev EI. Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes. Thromb Res. 2014;134:121–4.CrossRef Singer J, Weissler Snir A, Leshem-Lev D, Rigler M, Kornowski R, Lev EI. Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes. Thromb Res. 2014;134:121–4.CrossRef
31.
Zurück zum Zitat Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.CrossRef Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.CrossRef
32.
Zurück zum Zitat Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Jama. 2008;300:2134–41.CrossRef Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Jama. 2008;300:2134–41.CrossRef
33.
Zurück zum Zitat Trovati M, Anfossi G, Cavalot F, Vitali S, Massucco P, Mularoni E, Schinco P, Tamponi G, Emanuelli G. Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes. 1986;35:818–25.CrossRef Trovati M, Anfossi G, Cavalot F, Vitali S, Massucco P, Mularoni E, Schinco P, Tamponi G, Emanuelli G. Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes. 1986;35:818–25.CrossRef
34.
Zurück zum Zitat Mikhailidis DP, Barradas MA, Jeremy JY, Dandona P. Effect of alpha a-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:147–9.CrossRef Mikhailidis DP, Barradas MA, Jeremy JY, Dandona P. Effect of alpha a-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:147–9.CrossRef
35.
Zurück zum Zitat Takeda H, Kishikawa H, Shinohara M, Miyata T, Suzaki K, Fukushima H, Ichinose K, Shichiri M. Effect of alpha 2-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1988;31:657–63.CrossRef Takeda H, Kishikawa H, Shinohara M, Miyata T, Suzaki K, Fukushima H, Ichinose K, Shichiri M. Effect of alpha 2-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1988;31:657–63.CrossRef
36.
Zurück zum Zitat Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362–72.CrossRef Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362–72.CrossRef
37.
Zurück zum Zitat Kishikawa H, Takeda H, Kiyota S, Sakakida M, Fukushima H, Ichinose K, Matsuda H, Nakamura N, Uzawa H. Role of alpha 2-adrenergic receptor in platelet activation during insulin-induced hypoglycemia in normal subjects. Diabetes. 1987;36:407–12.CrossRef Kishikawa H, Takeda H, Kiyota S, Sakakida M, Fukushima H, Ichinose K, Matsuda H, Nakamura N, Uzawa H. Role of alpha 2-adrenergic receptor in platelet activation during insulin-induced hypoglycemia in normal subjects. Diabetes. 1987;36:407–12.CrossRef
38.
Zurück zum Zitat Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–84.CrossRef Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–84.CrossRef
39.
Zurück zum Zitat Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J. Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol. 1979;32:434–8.CrossRef Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J. Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol. 1979;32:434–8.CrossRef
40.
Zurück zum Zitat De Caterina R, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010;31:1557–64.CrossRef De Caterina R, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010;31:1557–64.CrossRef
41.
Zurück zum Zitat Arima Y, Kaikita K, Ishii M, Ito M, Sueta D, Oimatsu Y, Sakamoto K, Tsujita K, Kojima S, Nakagawa K, et al. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J Thromb Haemost. 2016;14:850–9.CrossRef Arima Y, Kaikita K, Ishii M, Ito M, Sueta D, Oimatsu Y, Sakamoto K, Tsujita K, Kojima S, Nakagawa K, et al. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J Thromb Haemost. 2016;14:850–9.CrossRef
42.
Zurück zum Zitat Idemoto Y, Miura SI, Norimatsu K, Suematsu Y, Hitaka Y, Shiga Y, Morii J, Imaizumi S, Kuwano T, Iwata A, et al. Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation analysis system((R)). Heart Vessel. 2017;32:309–16.CrossRef Idemoto Y, Miura SI, Norimatsu K, Suematsu Y, Hitaka Y, Shiga Y, Morii J, Imaizumi S, Kuwano T, Iwata A, et al. Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation analysis system((R)). Heart Vessel. 2017;32:309–16.CrossRef
43.
Zurück zum Zitat Ishii M, Kaikita K, Ito M, Sueta D, Arima Y, Takashio S, Izumiya Y, Yamamoto E, Yamamuro M, Kojima S, et al. Direct Oral anticoagulants form Thrombus different from warfarin in a microchip flow chamber system. Sci Rep. 2017;7:7399.CrossRef Ishii M, Kaikita K, Ito M, Sueta D, Arima Y, Takashio S, Izumiya Y, Yamamoto E, Yamamuro M, Kojima S, et al. Direct Oral anticoagulants form Thrombus different from warfarin in a microchip flow chamber system. Sci Rep. 2017;7:7399.CrossRef
Metadaten
Titel
Effects of glycemic control and hypoglycemia on Thrombus formation assessed using automated microchip flow chamber system: an exploratory observational study
verfasst von
Kiyoaki Yamamoto
Takashi Ito
Tomoka Nagasato
Atsushi Shinnakasu
Mihoko Kurano
Aiko Arimura
Hiroshi Arimura
Hiroshi Hashiguchi
Takahisa Deguchi
Ikuro Maruyama
Yoshihiko Nishio
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
Thrombosis Journal / Ausgabe 1/2019
Elektronische ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-019-0206-8

Weitere Artikel der Ausgabe 1/2019

Thrombosis Journal 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.